PDF(Pubmed)
Abstract：
OBJECTIVE: This study aimed to evaluate inflammatory biomarkers in patients undergoing peritoneal dialysis and investigate their association with all-cause mortality or transfer to hemodialysis.
METHODS: This prospective cohort study included 43 patients undergoing peritoneal dialysis. Plasma levels of cytokines were measured using flow cytometry and capture enzyme-linked immunosorbent assay. Biomarkers were categorized based on their respective median values. Survival analysis was conducted using the Kaplan-Meier estimator, considering two outcomes: all-cause mortality and transfer to hemodialysis.
RESULTS: After adjusting for confounding factors, plasma levels above the median of the levels of CCL2 and plasma, as well as below the median of TNF-α, and the median of dialysate IL-17 levels, were associated with an increased risk of experiencing the specified outcomes after approximately 16 months of follow-up.
CONCLUSIONS: These findings suggest that inflammatory biomarkers may be a valuable tool for predicting all-cause mortality and transfer to hemodialysis in patients undergoing peritoneal dialysis.
METHODS: This prospective cohort study included 43 patients undergoing peritoneal dialysis. Plasma levels of cytokines were measured using flow cytometry and capture enzyme-linked immunosorbent assay. Biomarkers were categorized based on their respective median values. Survival analysis was conducted using the Kaplan-Meier estimator, considering two outcomes: all-cause mortality and transfer to hemodialysis.
RESULTS: After adjusting for confounding factors, plasma levels above the median of the levels of CCL2 and plasma, as well as below the median of TNF-α, and the median of dialysate IL-17 levels, were associated with an increased risk of experiencing the specified outcomes after approximately 16 months of follow-up.
CONCLUSIONS: These findings suggest that inflammatory biomarkers may be a valuable tool for predicting all-cause mortality and transfer to hemodialysis in patients undergoing peritoneal dialysis.
摘要：
目的：本研究旨在评估腹膜透析患者的炎症生物标志物，并探讨其与全因死亡率或血液透析转移的关系。
方法：本前瞻性队列研究包括43例腹膜透析患者。使用流式细胞术和捕获酶联免疫吸附测定测量细胞因子的血浆水平。基于其各自的中值对生物标志物进行分类。使用Kaplan-Meier估计器进行生存分析，考虑两个结果：全因死亡率和血液透析转移。
结果：调整混杂因素后，血浆水平高于CCL2和血浆水平的中位数，以及低于TNF-α的中位数，和透析液IL-17水平的中位数，在大约16个月的随访后,与经历特定结局的风险增加相关.
结论：这些研究结果表明，炎症生物标志物可能是预测腹膜透析患者全因死亡率和血液透析转移的有价值的工具。
方法：本前瞻性队列研究包括43例腹膜透析患者。使用流式细胞术和捕获酶联免疫吸附测定测量细胞因子的血浆水平。基于其各自的中值对生物标志物进行分类。使用Kaplan-Meier估计器进行生存分析，考虑两个结果：全因死亡率和血液透析转移。
结果：调整混杂因素后，血浆水平高于CCL2和血浆水平的中位数，以及低于TNF-α的中位数，和透析液IL-17水平的中位数，在大约16个月的随访后,与经历特定结局的风险增加相关.
结论：这些研究结果表明，炎症生物标志物可能是预测腹膜透析患者全因死亡率和血液透析转移的有价值的工具。
